Cargando…
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity
Drug resistance and tumor heterogeneity limits the therapeutic efficacy in treating glioblastoma, an aggressive infiltrative type of brain tumor. GBM cells develops resistance against chemotherapeutic agent, temozolomide (TMZ), which leads to the failure in treatment strategies. This enduring challe...
Autores principales: | Doan, Phuong, Nguyen, Phung, Murugesan, Akshaya, Candeias, Nuno R., Yli-Harja, Olli, Kandhavelu, Meenakshisundaram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393831/ https://www.ncbi.nlm.nih.gov/pubmed/34440745 http://dx.doi.org/10.3390/cells10081975 |
Ejemplares similares
-
Synthesis and Preclinical
Validation of Novel Indole
Derivatives as a GPR17 Agonist for Glioblastoma Treatment
por: Nguyen, Phung, et al.
Publicado: (2021) -
Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol through the Modulation of EGFR and CSC Signaling Pathways
por: Doan, Phuong, et al.
Publicado: (2020) -
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway
por: Doan, Phuong, et al.
Publicado: (2019) -
P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer
por: Le, Hien Thi Thu, et al.
Publicado: (2022) -
Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth
por: Doan, Phuong, et al.
Publicado: (2021)